Global Cancer Supportive Care Drugs Market
Cancer supportive care also known as palliative care is focused on relieving patients from the side effects of cancer therapies. In cancer palliative care, supportive drugs are used to lessen the side effects of cancer treatments. In many cases, cancer treatments need to be stopped or the dose needs to be lowered due to various reasons such as low blood cell counts. In such cases, supportive drugs such as CSFs enable patients to continue with cancer treatments as well as in other cases, it also allows higher doses of cancer therapies.
Market Size &Growth Rate:
The cancer supportive care drugs market was valued at USD 18.68 billion in 2021 and is expected to reach USD 21.42 billion by 2027, exhibiting a CAGR of 2.4 % during the forecast period 2022-2027. The growth could be attributed to the return of demand to pre-pandemic levels, increasing authorization of novel & innovative medicines, extensive research, disease prevalence, and immunotherapies.
Market Dynamics:
Cancer-supportive care products are intended to help patients cope with the adverse effects of treatment. As a result, rising cancer rates are directly connected to the expansion of these cancer-supportive care drugs.According to the WHO-2021, cancer is the largest cause of mortality worldwide, recorded nearly 10 million fatalities in 2020, or approximately one in every six deaths, and 400000 children are diagnosed with the disease. Moreover, according to Globocan 2021, the new cancer cases that were diagnosed accounted for 19.3 million in 2021 globally, with 10.0 million deaths due to cancer.
In February 2021, Biocon Biologics Ltd. agreements with the Clinton Health Access Initiative to expand the approach to treat significant cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP).
The partnership is a significant process in delivering novel cancer therapies to patients who need them the most and ensuring equitable access to high-quality biosimilars in low & middle-income countries (LMICs) and it is positively reflecting the cancer-supportive care drugs market growth.
According to WHO-2022, the breast cancer segment is projected 2.4 million new cases followed by lung cancer across the globe, as breast cancer is the first line of impact for cancer supportive care drugs.
Get more details on this report - Request Free Sample
Market Drivers:
-
Growing demand for Granulocyte Colony-Stimulating Factors (G-CSFs)
-
The G-CSF segment consists of sales of G-CSF drugs and related services. G-CSF drugs are used to treat granulocytopenia and neutropenia after chemotherapy for cancer patients.
-
One of the main types of G-CSF lenograstim is a glycosylated recombinant therapeutic drug that is chemically similar to a naturally occurring human granulocyte colony stimulating factor. The different products including tablets, capsules, and others are used in oncological diseases, blood disorders, growth hormone deficiencies, chronic and autoimmune disorders, and others.
-
The increasing prevalence of cancer is a key factor driving the growth of the G-CSF platform, thus, increasing cancer would increase the demand for cancer-supportive segments like G-CSF for treatment.
-
Increasing prevalence of cancer and adverse effects associated with the use of cancer drugs
-
Approvals and launch of new products
Challenges:
-
High cost of cancer supportive care drugs (G-CSFs)
-
The high cost is a key factor limiting the growth of the cancer-supportive care drugs market, such as G-CSF segment. Improved chemotherapy administration is responsible for the rise in instant medical growth in breast cancer patients receiving primary prophylactic PP G-CSF. According to the American journal of managed care, PPG-CSF administration in the first chemotherapy segment was associated with a 57% increase in total medicare costs, despite a fall in medical costs for granulocytopenia.
-
About 42% of the increase can be attributed to an increase in chemotherapy costs. Each step of PPG-CSF costs more than USD 250. Therefore, the high cost is expected to hinder the growth of the G-CSF platform, it impacts the cancer-supportive care drugs market.
-
Stringent regulatory process
Competitive landscape:
Amgen Inc., Helsinn Healthcare, Baxter International, Fagron Group, Teva Pharmaceutical Inc., Kyowa Hakko Kirin, Heron Pharma, Johnson & Johnson, Merck & Co. Inc, Novartis (Sandoz), Hoffmann-La Roche, Acacia Pharma Group Plc, Sanofi, Sun Pharmaceutical Industries Ltd., Celldex Therapeutics, Ipsen Pharma and Others.
Key Developments:
Get more details on this report - Request Free Sample